Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies

Treatment of advanced (metastatic) non-small-cell lung cancer (NSCLC) is currently mainly based on immunotherapy with antibodies against PD-1 or PD-L1, alone, or in combination with chemotherapy. In locally advanced NSCLC and in early resected stages, immunotherapy is also employed. Tumor PD-L1 expr...

Descripción completa

Detalles Bibliográficos
Autores principales: Santarpia, Mariacarmela, Aguilar, Andrés, Chaib, Imane, Cardona, Andrés Felipe, Fancelli, Sara, Laguia, Fernando, Bracht, Jillian Wilhelmina Paulina, Cao, Peng, Molina-Vila, Miguel Angel, Karachaliou, Niki, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352732/
https://www.ncbi.nlm.nih.gov/pubmed/32516941
http://dx.doi.org/10.3390/cancers12061475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352732/
https://www.ncbi.nlm.nih.gov/pubmed/32516941
http://dx.doi.org/10.3390/cancers12061475

Ejemplares similares